Ian Goodfellow
@igoodfel
Antivirals at Exscientia - AI-driven pharmatech. Virologist at the University of Cambridge and University of Makeni, Sierra Leone. Views my own. exscientia.ai
ID: 233935521
http://exscientia.ai 04-01-2011 13:19:06
5,5K Tweet
5,5K Followers
753 Following
Explore “functionally-directed multi-omics (FDMO)” at #ISMBECCB2023 poster 1374 presented by Pisanu Ize Buphamalai, which augments multi-omics with functional data from highthroughput ex vivo screens in primary cancer samples for target ID & drug repurposing bit.ly/ISMB_1374
Can structural biology prevent the next #pandemic? Many thanks to the PAD initiative and Novo Nordisk Foundation for funding a Rhodes University🇿🇦+Cambridge University🇬🇧 collaboration to test if we can make antiviral drugs that are immune to resistance mutations! padinitiative.com/awarded-grants… Ian Goodfellow
Have a listen to Exscientia's CEO Andrew Hopkins talk to Alice Hopkins (no relation!) on BBC Oxfordshire about the use of AI in drug discovery & precision medicine (at 1.47.00) - inbetween the Pet Shop Boys and Otis Reading - nice! #EXAI; bbc.co.uk/sounds/play/p0…
Very much looking forward to working with Ozlem Tastan Bishop and Stephen Graham's Lab on this project. The project uses a fantastic combination of computational and biochemical approaches to probe mechanism of antiviral drug resistance.
Exscientia will start a new #AI drug discovery collaboration with Merck Healthcare, combining our AI-driven precision design capabilities with Merck’s oncology & I&I expertise, clinical capabilities. ($20M u/f, $674M total to $EXAI); investors.exscientia.ai/press-releases…
Thank you to the Asia PGI for hosting ARTIC Network as trainers for the first Oxford Nanopore sequencing workshop. Amazing teams, flu libraries and metagenomic trouble shooting 🦠🧬🕵️
We’re hiring! Looking for a structural enzymologist to join a 🇬🇧+🇿🇦 collaboration to understand how viral enzymes evolve resistance to antiviral drugs. Details: padinitiative.com/awarded-grants… Apply: jobs.cam.ac.uk/job/42708/ Come work with us to help save the world from the next pandemic!
Announcing the presentation of 2 posters at #ESMO23 highlighting new preclinical data for our LSD1 and MALT1 inhibitors, underlining how we bring together AI design & novel translational research capabilities aiming to create better quality drug candidates investors.exscientia.ai/press-releases…
Congratulations to our Lucy Thorne, Lecturer in Molecular Virology, for winning Microbiology Society's Peter Wildy Prize 2024! 🎉 The prize is awarded for outstanding contributions to microbiology education or the communication of microbiology to the public. 👉microbiologysociety.org/news/society-n…
Congratulations Lucy Thorne
Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza. $EXAI Exscientia investors.exscientia.ai/press-releases…
We’re proud to announce that we’ve been awarded an Open Philanthropy Pandemic Antiviral Discovery (PAD) grant to explore new therapeutic approaches for pandemic influenza, researching the activation of the interferon response against influenza and COVID-19. padinitiative.com/awarded-grants…
Heartbreaking news: my friend and colleague 𝙱𝚛𝚎𝚝𝚝 𝙻𝚒𝚗𝚍𝚎𝚗𝚋𝚊𝚌𝚑 🌊 has died after battling glioblastoma. Brett was an outstanding virologist who leaves a legacy of monumental contributions to our field. He was also great company to drink bourbon with. legacy.com/us/obituaries/…
In honor of 𝙱𝚛𝚎𝚝𝚝 𝙻𝚒𝚗𝚍𝚎𝚗𝚋𝚊𝚌𝚑 🌊, check out Molly & Claire Lindenbach's "Lemon-Aid” Stand for Dad's fundraising page - nbtsevents.braintumor.org/fundraiser/394…
Really pleased to report that Exscientia $EXAI have partnered an ongoing discovery program with Sanofi $SNY. Deal terms include $45M in upfront & preclinical m/s & an additional $300M plus royalties, beyond that. 🥳🥂 Exscientia #AI #biotech $XBI investors.exscientia.ai/press-releases…